24 protocols found



Protocol No. Title Status
ANBL1531 A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) Open
UW17082 A Phase II, Open-Label, Non-Controlled, Intra-Patient Dose-Escalation Study to Characterize the Pharmacokinetics after Oral Administration of Eltrombopag in Pediatric Patients with Refractory, Relapsed, or Treatment Naïve Severe Aplastic Anemia or Recurrent Aplastic Anemia Open
UW18084 A Phase II, Single Arm, Multicenter Open Label Trial to Determine the Safety and Efficacy of Tisagenlecleucel in Pediatric Patients with Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma (NHL) (BIANCA), C2202 Open
UW18143 A Randomized Trial of Low vs. Moderate Exposure Busulfan for Infants with Severe Combined Immunodeficiency (SCID) Receiving TCR alpha beta+/CD19+ Depleted Transplantation: A Phase II study by the Primary Immune Deficiency Treatment Consortium (PIDTC) and Pediatric Blood and Marrow Transplant Consortium (PBMTC) Open
BMTCTN1702 Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (CTRL-ALT-D) Open
UW16132 LCH-IV: International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis Open
ALTE15N2 LEAHRN (Late Effects After High-Risk Neuroblastoma) Study Open
ADVL1823 Larotrectinib (LOXO-101, NSC# 788607, IND# 141824) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias Open
UW16075 MiNivAN; A Phase 1 study of 131-I mIBG followed by Nivolumab and Dinutuximab beta Antibodies in children with relpased/refractory Neuroblastoma Open
APEC1621H NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Olaparib in Patients with Tumors Harboring Defects in DNA Damage Repair Genes. Open
APEC1621G NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Vemurafenib in Patients with Tumors Harboring Braf V600 Mutations Open
APEC1621SC NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol Open
APEC1621J NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)-Phase 2 Subprotocol of BVD-523FB (ulixerlinib) in Patients with Tumors Harboring Activating MAPK Pathway Mutations Open
APEC1621D NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)-Phase 2 Subprotocol of LY3023414 in Patients with Solid Tumors Open
APEC1621I NCI-COG Pediatric Match(MOLECULAR ANALYSIS FOR THERAPY CHOICE)-Phase 2 Subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes Open
UW16124 Pediatric myelodysplastic syndrome and bone marrow failure disorder patient registry and tissue repository Open
APEC14B1 Project: Every Child A Registry, Eligibility Screening, Biology and Outcome Study Open
UW17025 Radiation- and alkylator-free hematopoietic cell transplantation for bone marrow failure due to dyskeratosis congenita / telomere disease. Open
AAML1531 Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome Open
UW19082 Symptom Burden, Co-Occurrence, and Trajectories in Children with Advanced Cancer Open
UW13090 TCR-a/b+ and CD19+ depleted KIR/KIR ligand-mismatched Haploidentical Hematopoietic Stem Cell Transplant and Zoledronate for Pediatric Relapsed/Refractory Hematologic Malignancies and High Risk Solid Tumors Open
ACCL1633 The Effectiveness of Lactobacillus plantarum (LBP, IND# 17339) in Preventing Acute Graft-versus-Host Disease (GvHD) in Children undergoing Alternative Hematopoietic Progenitor Cell Transplantation (HCT) Open
UW18073 Treatment of CMV Infections with Viral-Specific T Cells Against CMV in Pediatric and Adult Immunocompromised Patients or Recipients of Allogeneic Stem Cell Transplantation Open
UW19015 Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia (TransIT) PBMTC NMD1601 Open